Phase 1 clinical test now delayed by 6 months.I get it that the...

Phase 1 clinical test now delayed by 6 months.

I get it that the main game for this bunch of retirees () and academics is the disruption, nay, revolution, of microbiome analysis and treatment becoming a mainstay of health care where "you are what you eat" becomes more than an annoying mum-ism. But that will not put food on the table for MAP shareholders anytime soon.

For a listed company, the horizon does not extend much past the next set of quarterly results. They say they have up to 20 potential distribution partners for their testing services. Great! But great only if that shows through in increasing rates of sales growth - not only do the new sign-ups need to bring in extra sales but the existing partners need to be rapidly growing their sales of Microba services. It's impressive that the likes of Ian Frazer is onboard with the great potential of Microba but I would like to see revenue metrics front and centre for the company.